Global Extensively Drug Resistant Tuberculosis (XDR-TB) Treatment Market, By Treatment Type (First Line Anti-TB Drugs, Second-Line Anti-TB Drugs, Others), Route of Administration (Oral, Parenteral, Others), End-User (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy), Country (U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa) Industry Trends and Forecast to 2028
Market Analysis and Insights: Global Extensively Drug Resistant Tuberculosis (XDR-TB) Treatment Market
The extensively drug resistant tuberculosis (XDR-TB) treatment market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses the market is growing at a CAGR of 8.10% in the above-mentioned research forecast period. Ongoing research on extensively drug resistant tuberculosis (XDR-TB) is the factor for the growth of extensively drug resistant tuberculosis (XDR-TB) treatment market.
For instance,
- Pretomanid is a novel compound which is developed by non-profit organization TB Alliance which had received FDA approval. This drug will be taken with the combination of bedaquiline and linezolid. This novel compound is used for the treatment of highly drug-resistant forms of tuberculosis such as extensively drug resistant tuberculosis.
Extensively drug resistant tuberculosis (XDR-TB) is characterized by the tuberculosis strain which is resistant to rifampicin and isoniazid. It is also resistant to the fluoroquinolone and from the one of the injection used for the treatment such as capreomycin, kanamycin and amikacin. XDR-TB was first discovered in 2006 and is considered as novel and incurable disease.
Increase in patient population suffering from tuberculosis and extensively drug resistant tuberculosis (XDR-TB) may drive the extensively drug resistant tuberculosis (XDR-TB) treatment market growth. According to World Health Organization (WHO), there are 5,58,000 cases of drug resistant tuberculosis from which 8.5% cases are of XDR-TB and the treatment outcome for XDR-TB is 34%. There are 4,65,000 cases of rifampicin resistant tuberculosis in 2019. Increase in initiatives taken by the organizations such as World Health Organization (WHO) and institutes such as Centers for Disease Control and Prevention may also drive the extensively drug resistant tuberculosis (XDR-TB) treatment market growth. HIV patients associated with tuberculosis are at high risk of having extensively drug resistant tuberculosis (XDR-TB) which may drive the extensively drug resistant tuberculosis (XDR-TB) treatment market growth. Unavailability of clinical approaches of XDR-TB and as the treatment is complicated and expensive with less cure and high mortality rate which may hamper the extensively drug resistant tuberculosis (XDR-TB) treatment market growth. For instance, the treatment cost of XRD-TB in the United States is USD 164,000.
This extensively drug resistant tuberculosis (XDR-TB) treatment market provides details of market share, new developments and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions and technological innovations in the market. To understand the analysis and the extensively drug resistant tuberculosis (XDR-TB) treatment market scenario contact Data Bridge Market Research for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.
Extensively Drug Resistant Tuberculosis (XDR-TB) Treatment Market Scope and Market Size
The extensively drug resistant tuberculosis (XDR-TB) treatment market is segmented on the basis of treatment type, route of administration, end-user and distribution channel. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
- On the basis of treatment type, the extensively drug resistant tuberculosis (XDR-TB) treatment market is segmented into first line anti-TB drugs, second line anti-TB drugs and others. First line anti-TB drugs are further segmented to isoniazid, rifampicin, ethambutol, pyrazinamide, and others. Second line anti-TB drugs are further segmented to levofloxacin, moxifloxacin, bedaquiline, delamanid and linezolid.
- On the basis of route of administration, the extensively drug resistant tuberculosis (XDR-TB) treatment market is segmented into oral, parenteral and others.
- On the basis of end-user, the extensively drug resistant tuberculosis (XDR-TB) treatment market is segmented to hospitals, homecare, specialty clinics and others.
- On the basis of distribution channel, the extensively drug resistant tuberculosis (XDR-TB) treatment market is segmented into hospital pharmacy, online pharmacy and retail pharmacy.
Global Extensively Drug Resistant Tuberculosis (XDR-TB) Treatment Market Country Level Analysis
Global extensively drug resistant tuberculosis (XDR-TB) treatment market is analysed and market size information is provided by country, treatment type, route of administration, end-user and distribution channel as referenced above.
The countries covered in the extensively drug resistant tuberculosis (XDR-TB) treatment market report are the U.S., Canada, Mexico in North America, Brazil, Argentina, Peru, Rest of South America, as part of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa, as a part of Middle East and Africa.
On geographical estimation, North America has been witnessing a positive growth for extensively drug resistant tuberculosis (XDR-TB) treatment market throughout the forecasted period owing to the global leaders in research and development activities, established framework of approval process and high adoption of BCG vaccine. Europe is considered as the second largest growing regional segment due to the high cases of XDR-TB and presence of community centres. Asia-Pacific leads the extensively drug resistant tuberculosis (XDR-TB) treatment market due to the developing healthcare facilities, large number of generic manufacturers and rise in government initiatives and specialist communities.
The country section of the report also provides individual extensively drug resistant tuberculosis (XDR-TB) treatment market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Patient Epidemiology Analysis
The extensively drug resistant tuberculosis (XDR-TB) treatment market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to extensively drug resistant tuberculosis (XDR-TB) treatment market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the extensively drug resistant tuberculosis (XDR-TB) treatment market in the growth period.
Competitive Landscape and Global Extensively Drug Resistant Tuberculosis (XDR-TB) Treatment Market Share Analysis
The extensively drug resistant tuberculosis (XDR-TB) treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to global extensively drug resistant tuberculosis (XDR-TB) treatment market.
The major players covered in the global extensively drug resistant tuberculosis (XDR-TB) treatment market report are Sanofi, Novartis AG, Endo International plc, CMP Pharma, STI Pharma, LLC, Akorn Incorporated, Lupin, Johnson & Johnson Services, Inc., Macleods Pharmaceuticals Ltd, Pfizer Inc, Hikma Pharmaceuticals PLC, Lannett, Mylan N.V., Teva Pharmaceutical Industries Ltd and Fresenius Kabi AG among other domestic and global players. Market share data is available for global, North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South America separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.
SKU-
